Hims & Hers Health: The Company Will Survive, But Investors Should Expect A 'Washout' [Seeking Alpha]
Hims & Hers Health, Inc. Class A (HIMS)
Company Research
Source: Seeking Alpha
Despite the GLP-1 setback, 70% of HIMS' projected $2.35B FY25 revenue is from non-weight loss segments, supporting a resilient core business. HIMS' $1.07B liquidity and 0% convertible notes provide a fortress balance sheet, enabling survival through the current pivot. Analyst and management expectations remain too optimistic in my view; further estimate cuts and clarity on GLP-1 exposure are needed before a buying opportunity emerges. Lock Stock/DigitalVision via Getty Images Over the weekend, Hims & Hers Health ( HIMS announced that it will no longer offer a compounded version of oral semaglutide, the active ingredient in Novo Nordisk's ( NVO ) weight loss This article was written by Analyst's Disclosure: I/we have a beneficial short position in the shares of NVO either through stock ownership, options, or other derivatives. I wrote this article myself, and it expresses my own opinions. I am not receiving compensation for it (other than from Seeking Alpha). I have no bus
Show less
Read more
Impact Snapshot
Event Time:
HIMS
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
HIMS alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
HIMS alerts
High impacting Hims & Hers Health, Inc. Class A news events
Weekly update
A roundup of the hottest topics
HIMS
News
- Hims & Hers Health (NYSE:HIMS) was given a new $31.00 price target on by analysts at Deutsche Bank Aktiengesellschaft. They now have a "hold" rating on the stock.MarketBeat
- Hims & Hers Health: The GLP-1 Trade Just Got Real (Rating Downgrade) [Seeking Alpha]Seeking Alpha
- Hims & Hers Health, Inc. (HIMS) Stock Dips While Market Gains: Key Facts [Yahoo! Finance]Yahoo! Finance
- Hims & Hers Health: Don't Fall For The Hysteria [Seeking Alpha]Seeking Alpha
- HIMS Investors Have Opportunity to Join Hims & Hers Health, Inc. Fraud Investigation with the Schall Law FirmBusiness Wire
HIMS
Earnings
- 11/3/25 - Miss
HIMS
Sec Filings
- 2/4/26 - Form 4
- 1/21/26 - Form 4
- 1/20/26 - Form 144
- HIMS's page on the SEC website